Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata) on June 26, 2014. The report details the entry into a material definitive agreement for an underwritten registered direct offering of securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: The Company expects to receive approximately $24.0 million in gross proceeds, before underwriting discounts, commissions, and estimated offering expenses.
- Series A Units: Up to 5,559,866 units offered at $3.48 per unit. Each unit consists of one share of common stock and a warrant to purchase 0.5 shares at an exercise price of $4.00.
- Series B Units: Up to 1,340,538 units offered at $3.47 per unit. These are reserved for purchasers who would otherwise exceed 9.99% beneficial ownership. Each unit consists of a Pre-Funded warrant (exercise price $0.01) and a warrant to purchase 0.5 shares at $4.00.
- Warrant Terms: All warrants are exercisable from the date of issuance until the fifth anniversary.
- Underwriter: Stifel, Nicolaus & Company, Incorporated.
- Closing Date: Expected on or about July 2, 2014.
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics. Those figures are referenced as being available in the Company's Form 10-K and 10-Q filings.
Material Changes
The primary material change is the execution of the Underwriting Agreement on June 26, 2014, which authorizes the sale of the equity securities described above. This represents a significant capital raise intended to fund the Company's operations and development programs.
Outlook, Risks, and Management Commentary
- Forward-Looking Statements: The filing contains forward-looking statements regarding the intention to complete the offering. Actual results may differ due to risks including the ability to manage the offering successfully and general economic conditions.
- Regulatory Status: Securities were registered under Rule 415 on a delayed or continuous basis via a Form S-3 declared effective on November 30, 2012.
- Conditions: The transaction is subject to the satisfaction of customary closing conditions.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received after underwriting discounts.
- Review the Company's most recent Form 10-K (year ended Dec 31, 2013) and Form 10-Q (quarter ended March 31, 2014) for current liquidity and cash burn rates.
- Confirm the dilution impact of the new shares and warrants on existing shareholders.
- Check the prospectus supplement filed pursuant to Rule 424(b) for updated risk factors.